Skip to main content

2020 | Hormonsubstitution | OriginalPaper | Buchkapitel

41. Sexualhormone

verfasst von : Prof. Dr. med. Dr. h.c. Thomas Strowitzki

Erschienen in: Arzneiverordnungs-Report 2020

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Auf einen Blick

Verordnungsprofil Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Gestagene. Die Verordnungen aller Östrogenpräparate zur Hormontherapie in der Postmenopause (systemische und topische Präparate) sind seit 1999 stark zurückgegangen. Seit 2018 ist erstmals ein leichter Anstieg zu verzeichnen insbesondere bei Östrogenmonopräparaten. Damit wird auch 2019 der Effekt der Leitlinienempfehlungen zur postmenopausalen Hormontherapie mit weiterhin stabilen Verordnungszahlen sichtbar. Nach langjähriger Abnahme zeigten auch die Verordnungen der hormonalen Kontrazeptiva 2019 wieder eine deutliche Zunahme, insbesondere bei den Gestagenmonopräparaten und den vaginalen Kontrazeptiva. Testosteronverordnungen nehmen dagegen wie schon in den letzten Jahren weiter gering zu.
Bewertung Die Verordnungen zur postmenopausalen Hormontherapie reflektieren eine gute Beachtung der Indikationsstellung basierend auf einer sorgfältigen Nutzen-Risiko-Bewertung, die leitlinienbasiert erfolgt. Hormonersatztherapie soll in erster Linie bei klimakterischen Ausfallerscheinungen (z. B. vasomotorische und urogenitale Symptome) eingesetzt werden. Die überarbeitete deutsche S3-Leitlinie wurde 2020 veröffentlicht.
Literatur
Zurück zum Zitat American College of Obstetricians and Gynecologists (2013) Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121:887–890 CrossRef American College of Obstetricians and Gynecologists (2013) Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 121:887–890 CrossRef
Zurück zum Zitat Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122 PubMedPubMedCentralCrossRef Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122 PubMedPubMedCentralCrossRef
Zurück zum Zitat Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371:303–314 PubMedCrossRef Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371:303–314 PubMedCrossRef
Zurück zum Zitat Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007) Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840–845 PubMedCrossRef Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007) Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840–845 PubMedCrossRef
Zurück zum Zitat Chester RC, Kling JM, Manson JE (2018) What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 41:247–252 PubMedPubMedCentralCrossRef Chester RC, Kling JM, Manson JE (2018) What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 41:247–252 PubMedPubMedCentralCrossRef
Zurück zum Zitat Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, WHI Investigators (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692 PubMedPubMedCentralCrossRef Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, WHI Investigators (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692 PubMedPubMedCentralCrossRef
Zurück zum Zitat Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553 PubMedCrossRef Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553 PubMedCrossRef
Zurück zum Zitat Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36:123–129 PubMedCrossRef Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36:123–129 PubMedCrossRef
Zurück zum Zitat Ford O, Lethaby A, Roberts H, Mol BW (2012) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012:3–CD3415 (Mar 14) Ford O, Lethaby A, Roberts H, Mol BW (2012) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012:3–CD3415 (Mar 14)
Zurück zum Zitat Gronich N, Lavi I, Rennert G (2011) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. Canadian Medical Association Journal 183:E1319–1325 PubMedCrossRef Gronich N, Lavi I, Rennert G (2011) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. Canadian Medical Association Journal 183:E1319–1325 PubMedCrossRef
Zurück zum Zitat Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, WHI Investigators (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045 PubMedCrossRef Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, WHI Investigators (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045 PubMedCrossRef
Zurück zum Zitat Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589–1593 PubMedCrossRef Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589–1593 PubMedCrossRef
Zurück zum Zitat Keaney JF, Solomon CG (2016) Postmenopausal hormone therapy and atherosclerosis – Time is of the essence. N Engl J Med 374:1279–1280 PubMedCrossRef Keaney JF, Solomon CG (2016) Postmenopausal hormone therapy and atherosclerosis – Time is of the essence. N Engl J Med 374:1279–1280 PubMedCrossRef
Zurück zum Zitat Kemmeren JM, Algra A, Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323:1–9 CrossRef Kemmeren JM, Algra A, Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323:1–9 CrossRef
Zurück zum Zitat LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J, WHI Investigators (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314 PubMedPubMedCentralCrossRef LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J, WHI Investigators (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314 PubMedPubMedCentralCrossRef
Zurück zum Zitat Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257–2266 PubMedCrossRef Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257–2266 PubMedCrossRef
Zurück zum Zitat Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006) A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13:737–743 PubMedCrossRef Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006) A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13:737–743 PubMedCrossRef
Zurück zum Zitat Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368 PubMedCrossRef Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368 PubMedCrossRef
Zurück zum Zitat McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989) Progesterone cream for cyclic breast pain. Brit Med J 289:931 CrossRef McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989) Progesterone cream for cyclic breast pain. Brit Med J 289:931 CrossRef
Zurück zum Zitat Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291:1610–1620 PubMedCrossRef Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291:1610–1620 PubMedCrossRef
Zurück zum Zitat Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005) Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71:176–182 PubMedCrossRef Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005) Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71:176–182 PubMedCrossRef
Zurück zum Zitat Qaseem A, Horwitch CA, Vijan S, for the Clinical Guidelines Committee of the American College of Physicians et al (2020) Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Ann Intern Med 172:126–133 PubMedCrossRef Qaseem A, Horwitch CA, Vijan S, for the Clinical Guidelines Committee of the American College of Physicians et al (2020) Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Ann Intern Med 172:126–133 PubMedCrossRef
Zurück zum Zitat Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (2015) Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev 2015(8):CD11054 PubMedCentral Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (2015) Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev 2015(8):CD11054 PubMedCentral
Zurück zum Zitat Royal College of General Practitioners Oral Contraception Study (1981) Further analysis of mortality in oral contraceptive users. Lancet I:541–546 Royal College of General Practitioners Oral Contraception Study (1981) Further analysis of mortality in oral contraceptive users. Lancet I:541–546
Zurück zum Zitat Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434 PubMedCrossRef Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434 PubMedCrossRef
Zurück zum Zitat Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312:83–88 PubMedCrossRef Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312:83–88 PubMedCrossRef
Zurück zum Zitat Womens Health Initiative Steering Committee (2004) Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712 CrossRef Womens Health Initiative Steering Committee (2004) Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712 CrossRef
Zurück zum Zitat World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346:1582–1588 CrossRef World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346:1582–1588 CrossRef
Zurück zum Zitat Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333 CrossRef Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333 CrossRef
Zurück zum Zitat Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M (2013) Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. Br J Obstet Gynaecol 120:801–811 CrossRef Wu C, Grandi S, Filion K, Abenhaim H, Joseph L, Eisenberg M (2013) Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. Br J Obstet Gynaecol 120:801–811 CrossRef
Zurück zum Zitat Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928 PubMedCrossRef Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928 PubMedCrossRef
Metadaten
Titel
Sexualhormone
verfasst von
Prof. Dr. med. Dr. h.c. Thomas Strowitzki
Copyright-Jahr
2020
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-62168-4_41

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.